Aurinia Pharmaceuticals Inc
AUPH
查看详细走势图
14.440USD
+0.180+1.26%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.90B总市值
25.10市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.26%
5天
-0.62%
1月
-9.86%
6月
+26.33%
今年开始到现在
-9.47%
1年
+80.27%
查看详细走势图
TradingKey Aurinia Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Aurinia Pharmaceuticals Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名82/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价16.71。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aurinia Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Aurinia Pharmaceuticals Inc亮点
亮点风险
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
业绩高增长
公司营业收入稳步增长，连续3年增长75.43%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值25.10，处于3年历史合理位
机构加仓
最新机构持股66.87M股，环比增加0.10%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值1.45M
活跃度增加
近期活跃度增加，过去20天平均换手率0.56
分析师目标
根据
7
位分析师
买入
评级
16.714
目标均价
+14.64%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Aurinia Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aurinia Pharmaceuticals Inc简介
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
公司代码AUPH
公司Aurinia Pharmaceuticals Inc
CEOGreenleaf (Peter S)
网址https://www.auriniapharma.com
相关品种
